Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received January 23, 2019
- Accepted October 30, 2019
- Published online December 16, 2019.
Article Versions
- You are currently viewing a previous version of this article (December 16, 2019 - 04:58).
- View the most recent version of this article
Copyright & Usage
Copyright © 2019, Parenteral Drug Association
Author Information
- Aditya Prasad1,
- Philip Villari2,
- Robert 'Bo' Henry3,
- Jeffrey Weber4,
- James Hauschild5,
- Lisa Yan6,
- Jeff Horsch7,
- Shebeer Shereefa8,
- Jan Eric Rau9,
- Annett Milling10,
- Jay S Bolden11,
- Lucile Plourde12,
- Marja Claassen13,
- Pieta IJzerman-Boon13,
- Ren-Yo Forng14,
- Roland Portmann10,
- Simon Urwyler10 and
- Dawood Dassu15,16 (dawood{at}biophorum.com) (www.biophorum.com)
- 1 AstraZeneca;
- 2 Merck Inc.;
- 3 Catalent Biologics;
- 4 Pfizer;
- 5 Johnson & Johnson;
- 6 Takeda;
- 7 Bristol Myers Squibb;
- 8 Abbvie;
- 9 Lonza;
- 10 CSL Behring;
- 11 Eli Lilly;
- 12 Sanofi Pasteur;
- 13 Merck, Sharp & Dohme;
- 14 Amgen;
- 15 BioPhorum
- ↵* Corresponding author; email: dawood{at}biophorum.com
Cited By...
In This Issue
Jump to section
Related Articles
Cited By...
- A Commentary on "Understanding the Non-Equivalency of Bio-Fluorescent Particle Counts versus the Colony Forming Unit"
- Challenges Encountered in the Implementation of Bio-Fluorescent Particle Counting Systems as a Routine Microbial Monitoring Tool
- A Discussion on Bio-Fluorescent Particle Counters: Summary of the Process and Environmental Monitoring Methods Working Group Meeting with the FDA Emerging Technology Team